Skip to main content

Table 3 Genotype-matched clinical trials by drug class, somatic genotypes (variant level), and tumor type (n = 89)

From: Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial

Tumor type Somatic genotype (variant) Genotype-matching trial drug class Target lesion percent change
Colorectal No mutations (KRAS wildtype) EGFR −100 %
Breast PIK3CA E545K PI3K, Endocrine −90 %
Colorectal BRAF V600E BRAF, PI3K, EGFR −85 %
Colorectal BRAF V600E BRAF, PI3K, EGFR −81 %
TP53 S215G
Gynecological KRAS G13D PI3K, MEK −70 %
Gynecological PIK3CA H1047R VEGF −64 %
KRAS G12D
Gynecological KRAS G12V PI3K, MEK −63 %
Breast PIK3CA H1047R PI3K, IGF1R −61 %
Lung EGFR E746_A750del EGFR −58 %
EGFR T790M
Lung KRAS G13D MEK −54 %
Breast PIK3CA H1047R PI3K −50 %
Lung EGFR L858R EGFR −47 %
EGFR T790M
CTNNB1 S37C
Gynecological KRAS G12D MEK −47 %
Gynecological KRAS G12V PI3K, IGF1R −45 %
NRAS Q61R
Gynecological KRAS G12A PI3K, MEK −38 %
Breast PIK3CA N345K ANG2, MTOR −37 %
Lung KRAS G12D PI3K, MEK −37 %
Gynecological PIK3CA H1047R PI3K, MEK −37 %
KRAS G12D
Lung KRAS G12C MEK −28 %
Gynecological TP53 K132N WEE1 −26 %
Gynecological KRAS G12D PI3K, MEK −25 %
Colorectal BRAF V600E BRAF, PI3K, EGFR −24 %
TP53 R273C
PIK3CA Q546K
APC E1544X
Breast ERBB2 D769H HER2 −23 %
PIK3CA N345K
Upper aerodigestive BRAF V600E MEK −20 %
Lung KRAS G12S MEK −20 %
Gynecological KRAS G12D MEK, PI3K −20 %
Colorectal BRAF V600E BRAF, PI3K, EGFR −20 %
TP53 R175H
TP53 Q165X
Breast FGFR2 Y376C FGFR −19 %
Breast PIK3CA H1047L PI3K −18 %
Other GNAQ Q209P MEK −18 %
Lung EGFR L858R HER3, EGFR −18 %
Lung KRAS G12A PI3K, MEK −17 %
Lung EGFR L858R HER3, EGFR −17 %
Colorectal KRAS G12D PI3K, MEK −16 %
PIK3CA E545K
Gynecological KRAS G12V PI3K, MEK −16 %
Gynecological BRAF V600E MEK −15 %
Gynecological KRAS G12D PI3K, MEK −15 %
Lung KRAS G12V PI3K, MEK −13 %
Colorectal KRAS G12S MEK, EGFR −13 %
Gynecological NRAS Q61K PI3K, MEK −13 %
Pancreatobiliary KRAS G12V PI3K, IGF1R −13 %
Gynecological PIK3CA H1047R ANG2, mTOR −9 %
Breast PIK3CA E545K AKT −7 %
Colorectal KRAS G12V MEK, EGFR −7 %
Breast ERBB2 D769H PI3K, IGF1R −7 %
PIK3CA N345K
Lung KRAS G12V MEK −6 %
Colorectal ERBB2 L755S VEGF, ANG2 −6 %
BRAF N581S
ERBB2 L755S
APC Q1429fs
Genitourinary No mutations PI3K −5 %
PTEN negative on IHC
Lung EGFR L858R EGFR −4 %
Lung EGFR L858R EGFR −4 %
Lung EGFR E746_A750del EGFR −3 %
Breast PIK3CA H1047R AKT −3 %
Upper aerodigestive KRAS G12V PI3K, MEK −2 %
Gynecological KRAS G12D PI3K, MEK −2 %
Colorectal KRAS G13D MEK, EGFR −0.6 %
Genitourinary No mutations PI3K 0 %
PTEN negative on IHC
Breast PIK3CA H1047R PI3K 0 %
Colorectal PIK3CA E542K PI3K +0.5 %
KRAS G12V
Colorectal No Mutations (KRAS wildtype) MEK, EGFR +2 %
Colorectal KRAS G13D PI3K, MEK +2 %
PIK3CA E545K
Breast PIK3CA H1047L PI3K, IGF1R +4 %
Genitourinary No mutations PI3K +4 %
PTEN negative on IHC
Gynecological PIK3CA E545K MTOR +5 %
Breast PIK3CA N345K PI3K, IGF1R +6 %
Breast PIK3CA N345K PI3K, MEK +6 %
NRAS G12D
Gynecological PIK3CA C420R FGFR, PI3K +8 %
Colorectal KRAS G12D MEK, EGFR +9 %
Lung PIK3CA E545K PI3K, IGF1R +11 %
Colorectal No mutations (KRAS wildtype) MEK, EGFR +11 %
Colorectal KRAS G12D PI3K, MEK +12 %
PIK3CA Q546K
Gynecological PIK3CA H1047R PI3K, IGF1R +12 %
Breast PIK3CA p.Glu545Gly AKT +28 %
PTEN p.Leu320X
PIK3CA p.Arg93Gln
Gynecological TP53 R175H PI3K +29 %
PIK3CA R93W
FBXW7 R479Q
Colorectal KRAS G12D PI3K, MEK +30 %
PIK3CA E545K
Genitourinary PIK3CA p.Asn345Lys PI3K +31 %
Breast PIK3CA E545K FGFR, PI3K +32 %
Breast PIK3CA H1047R PI3K, IGF1R +39 %
Colorectal No mutations (KRAS wildtype) MEK, EGFR +55 %
Breast PIK3CA E542K PI3K, Endocrine +66 %
Breast PIK3CA N345K PI3K, IGF1R NE
Lung KRAS G12C PI3K, MEK NE
Breast PIK3CA H1047R PI3K, IGF1R NE
Lung KRAS G12A MEK NE
PIK3CA H1047R
Gynecological KRAS G12A PI3K, IGF1R NE
Breast PIK3CA E545K PI3K NE
TP53 L252del
BRAF c.1315-4C > G
Gynecological KRAS G12V MEK NE
Lung BRAF V600E MEK NE
Breast PIK3CA H1047L PI3K NE
TP53 C238Y
Other KIT V559A PI3K, EGFR NE